BioTime has entered into a research and option agreement with Orbit Biomedical regarding technology to deliver OpRegen to treat dry age-related macular degeneration, according to a press release.
Under the terms of the exclusive 12-month agreement, the companies will collaborate on the use of Orbit’s injection technology to deliver BioTime’s OpRegen to the subretinal space via a suprachoroidal route in an ongoing phase 1/2 clinical study.
“Orbit Biomedical’s specifically designed device offers surgeons an innovative solution for the delivery of therapies to the
Uncategorized